<div id="readability-page-1"><div> Across the US, cancer clinics have been thrown into a frenzy after the Food and Drug Administration authorized an expanded access program for Revolution Medicines (NASDAQ: RVMD)' experimental drug daraxonrasib, aimed at pancreatic cancer.The pharmaceutical company announced clinical trial results showing that daraxonrasib, a once-daily oral medication, approximately doubled median survival in patients with advanced pancreatic adenocarcinoma, improving it from 6.7 to 13.2 months compared to standard chemotherapy treatments.FDA's clearance for compassionate use came less than three weeks after those results were shared publicly, allowing patients previously treated for metastatic pancreatic cancer to get free access through selected cancer centers. This swift action reflects the severe unmet need in this disease, which claims around 53,000 lives annually in the US alone.Dr. Daniel King from the Zuckerberg Cancer Center noted an overwhelming influx of patient inquiries and referrals following the FDA announcement, with oncologists working hard to open protocols to offer the drug under this expanded program.But putting this access into motion is anything but straightforward. Physicians must submit detailed requests for each patient to Revolution Medicines for approval, and those cases then undergo FDA oversight. Institutional review boards have to monitor treatment, which adds layers of paperwork and resource strains amid already busy oncology clinics.Mark Goldsmith, CEO of Revolution Medicines, highlighted ongoing efforts to complete regulatory filings, though he stopped short of providing a timeline for full FDA approval or patient numbers expected to join the early access program.Meanwhile, high-profile patients, including former Senator Ben Sasse who disclosed his Stage 4 pancreatic cancer diagnosis, have publicly shared their involvement with daraxonrasib, further amplifying public attention.Experts like Dr. Gulam Manji from Columbia/NewYork-Presbyterian have called the drug a significant step forward - &#34;not a cure but a breakthrough to build on&#34; - given how few advancements have doubled survival rates for such a grim disease in recent memory.The true test will be how quickly the FDA processes the inevitable surge in requests amid maintaining safety oversight. How clinics navigate administrative hurdles and balance demand with supply could set a precedent for future expanded access scenarios in oncology. </div></div>

RVMD

LABU

SBIO

The FDA has authorized an expanded access program for Revolution Medicines' experimental drug daraxonrasib, aimed at pancreatic cancer, which has shown to double median survival rates. This decision allows patients with advanced pancreatic adenocarcinoma to access the drug through selected cancer centers. However, the process involves detailed requests and FDA oversight, creating administrative challenges for clinics. Experts view daraxonrasib as a significant advancement in treatment, though it is not a cure. The response to the surge in patient requests will be crucial for future access programs in oncology.

Stock Invest

Revolution Medicines

Direxion S&P Biotech Bull 3X

SPDR S&P Biotech

Invesco Biotechnology & Genome ETF

VanEck Biotech ETF

Proshares Ultra Nasdaq Biotech

First Trust NYSE Arca Biotech Index Fd

ALPS Medical Breakthrough

iShares Biotechnology ETF

REVOLUTION MEDICINES INC C/WTS 17/12/2026 (TO PUR COM)

US Cancer Clinics Rush to Access Revolutionary Pancreatic Cancer Drug Daraxonrasib